Indegene Limited has scheduled a series of one-on-one meetings with investors and analysts for August 24 and 25, 2026. The company issued the intimation pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The engagements will take place in both online and in-person formats, with officials from the company meeting various financial institutions and asset managers. Indegene explicitly stated that no unpublished price-sensitive information (UPSI) will be shared during these meetings.

Meeting schedule

The company outlined the specific dates, counterparties, and modes of interaction for the scheduled sessions.

Regulatory compliance

Indegene noted that the schedule is subject to change. The details of the meetings have been filed with BSE Limited and the National Stock Exchange of India Limited. Further information regarding the company's activities is available on its official website.

Indegene has authorized the execution of a definitive settlement agreement to resolve a class-action lawsuit involving its wholly-owned overseas subsidiary, Indegene, Inc. The company confirmed on August 19, 2026, that it has no further comments on the agreement following final clarifications from external counsel on August 18, 2026. The settlement remains subject to execution by relevant parties and approval by the U.S. District Court, District of New Jersey.

Settlement structure and financial impact

The lawsuit, Progressive Health and Rehab Corp. v. Indegene, Inc. et al., concerns alleged violations of the U.S. Telephone Consumer Protection Act, 1991 (TCPA) related to certain fax communications executed in February 2020. In July 2025, the court certified a class comprising approximately 18,851 unique fax numbers, representing 18,869 transmissions. The defendants' petition seeking permission to appeal this certification was denied, leading to mediation and subsequent negotiations.

The agreed settlement framework establishes a maximum settlement fund of approximately USD 4.72 million. This figure is derived from a payment of USD 250 per eligible approved claim. Crucially, the settlement is structured on a claims-made and reversionary basis. Indegene is not required to deposit or pre-fund the entire maximum amount upfront. Instead, actual payments will depend on the number of valid and approved claims submitted by class members. Any amounts not required to satisfy approved claims, along with other payments contemplated under the settlement, will revert to the defendants.

Administrative costs and next steps

The settlement does not constitute an admission of liability by Indegene or its subsidiary. The parties have identified Analytics as the settlement administrator, with estimated administration costs of approximately USD 42,559. The notice mechanics contemplate an initial fax notice, with fallback to U.S. First Class Mail where unsuccessful.

The next steps involve filing the settlement documentation with the court, obtaining preliminary approval, issuing class notices, and conducting claims administration. Final court approval is required before any payments are made to class members. The company will assess the accounting impact in accordance with applicable accounting standards once the process concludes.

What the Numbers Show

The reversionary nature of the settlement significantly mitigates the potential cash outflow for Indegene. While the maximum exposure is capped at USD 4.72 million, the actual financial impact will likely be lower, depending on the participation rate of the certified class. With an estimated administrative cost of only USD 42,559, the overhead for resolving this long-pending litigation is minimal relative to the maximum fund size. The absence of upfront funding requirements preserves liquidity, allowing the company to manage cash flows based on actual approved claims rather than a worst-case scenario.